Literature DB >> 20445351

Accelerated production of antigen-specific T cells for preclinical and clinical applications using gas-permeable rapid expansion cultureware (G-Rex).

Juan F Vera1, Lara J Brenner, Ulrike Gerdemann, Minhtran C Ngo, Uluhan Sili, Hao Liu, John Wilson, Gianpietro Dotti, Helen E Heslop, Ann M Leen, Cliona M Rooney.   

Abstract

The clinical manufacture of antigen-specific cytotoxic T lymphocytes (CTLs) for adoptive immunotherapy is limited by the complexity and time required to produce large numbers with the desired function and specificity. The culture conditions required are rigorous, and in some cases only achieved in 2-cm wells in which cell growth is limited by gas exchange, nutrients, and waste accumulation. Bioreactors developed to overcome these issues tend to be complex, expensive, and not always conducive to CTL growth. We observed that antigen-specific CTLs undergo 7 to 10 divisions poststimulation. However, the expected CTL numbers were achieved only in the first week of culture. By recreating the culture conditions present during this first week-low frequency of antigen-specific T cells and high frequency of feeder cells-we were able to increase CTL expansion to expected levels that could be sustained for several weeks without affecting phenotype or function. However, the number of 24-well plates needed was excessive and cultures required frequent media changes, increasing complexity and manufacturing costs. Therefore, we evaluated novel gas-permeable culture devices (G-Rex) with a silicone membrane at the base allowing gas exchange to occur uninhibited by the depth of the medium above. This system effectively supports the expansion of CTL and actually increases output by up to 20-fold while decreasing the required technician time. Importantly, this amplified cell expansion is not because of more cell divisions but because of reduced cell death. This bioprocess optimization increased T-cell output while decreasing the complexity and cost of CTL manufacture, making cell therapy more accessible.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20445351      PMCID: PMC2946348          DOI: 10.1097/CJI.0b013e3181c0c3cb

Source DB:  PubMed          Journal:  J Immunother        ISSN: 1524-9557            Impact factor:   4.456


  41 in total

1.  Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells.

Authors:  C Yee; J A Thompson; D Byrd; S R Riddell; P Roche; E Celis; P D Greenberg
Journal:  Proc Natl Acad Sci U S A       Date:  2002-11-11       Impact factor: 11.205

2.  Fiber-modified adenoviruses generate subgroup cross-reactive, adenovirus-specific cytotoxic T lymphocytes for therapeutic applications.

Authors:  Ann M Leen; Uluhan Sili; Barbara Savoldo; Alan M Jewell; Pedro A Piedra; Malcolm K Brenner; Cliona M Rooney
Journal:  Blood       Date:  2003-10-02       Impact factor: 22.113

3.  Manufacturing of large numbers of patient-specific T cells for adoptive immunotherapy: an approach to improving product safety, composition, and production capacity.

Authors:  Chy-Anh Tran; Luciana Burton; Diana Russom; Jamie R Wagner; Michael C Jensen; Stephen J Forman; David L DiGiusto
Journal:  J Immunother       Date:  2007-09       Impact factor: 4.456

4.  Single-pass, closed-system rapid expansion of lymphocyte cultures for adoptive cell therapy.

Authors:  Jacob A Klapper; Armen A Thomasian; Douglas M Smith; Gayle C Gorgas; John R Wunderlich; Franz O Smith; Brian S Hampson; Steven A Rosenberg; Mark E Dudley
Journal:  J Immunol Methods       Date:  2009-04-21       Impact factor: 2.303

5.  Commercially available gas-permeable cell culture bags may not prevent anoxia in cultured or shipped islets.

Authors:  E S Avgoustiniatos; B J Hering; P R Rozak; J R Wilson; L A Tempelman; A N Balamurugan; D P Welch; B P Weegman; T M Suszynski; K K Papas
Journal:  Transplant Proc       Date:  2008-03       Impact factor: 1.066

6.  T lymphocytes redirected against the kappa light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cells.

Authors:  Juan Vera; Barbara Savoldo; Stephane Vigouroux; Ettore Biagi; Martin Pule; Claudia Rossig; Jessie Wu; Helen E Heslop; Cliona M Rooney; Malcolm K Brenner; Gianpietro Dotti
Journal:  Blood       Date:  2006-08-22       Impact factor: 22.113

7.  Manufacturing validation of biologically functional T cells targeted to CD19 antigen for autologous adoptive cell therapy.

Authors:  Daniel Hollyman; Jolanta Stefanski; Mark Przybylowski; Shirley Bartido; Oriana Borquez-Ojeda; Clare Taylor; Raymond Yeh; Vanessa Capacio; Malgorzata Olszewska; James Hosey; Michel Sadelain; Renier J Brentjens; Isabelle Rivière
Journal:  J Immunother       Date:  2009 Feb-Mar       Impact factor: 4.456

8.  Regression of experimental medulloblastoma following transfer of HER2-specific T cells.

Authors:  Nabil Ahmed; Maheshika Ratnayake; Barbara Savoldo; Laszlo Perlaky; Gianpietro Dotti; Winfried S Wels; Meenakshi B Bhattacharjee; Richard J Gilbertson; H David Shine; Heidi L Weiss; Cliona M Rooney; Helen E Heslop; Stephen Gottschalk
Journal:  Cancer Res       Date:  2007-06-15       Impact factor: 12.701

9.  Co-expression of cytokine and suicide genes to enhance the activity and safety of tumor-specific cytotoxic T lymphocytes.

Authors:  Concetta Quintarelli; Juan F Vera; Barbara Savoldo; Greta M P Giordano Attianese; Martin Pule; Aaron E Foster; Helen E Heslop; Cliona M Rooney; Malcolm K Brenner; Gianpietro Dotti
Journal:  Blood       Date:  2007-07-17       Impact factor: 22.113

10.  Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes.

Authors:  H E Heslop; C Y Ng; C Li; C A Smith; S K Loftin; R A Krance; M K Brenner; C M Rooney
Journal:  Nat Med       Date:  1996-05       Impact factor: 53.440

View more
  74 in total

Review 1.  Genetic modification of T cells.

Authors:  Chiara Bonini; Malcolm K Brenner; Helen E Heslop; Richard A Morgan
Journal:  Biol Blood Marrow Transplant       Date:  2011-01       Impact factor: 5.742

2.  Adoptive T cell therapy for the treatment of viral infections.

Authors:  Reuben J Arasaratnam; Ann M Leen
Journal:  Ann Transl Med       Date:  2015-10

Review 3.  Adoptive T-cell therapies for refractory/relapsed leukemia and lymphoma: current strategies and recent advances.

Authors:  Lauren McLaughlin; C Russell Cruz; Catherine M Bollard
Journal:  Ther Adv Hematol       Date:  2015-12

Review 4.  Adoptive T cell therapy of cancer.

Authors:  Malcolm K Brenner; Helen E Heslop
Journal:  Curr Opin Immunol       Date:  2010-02-17       Impact factor: 7.486

5.  Expanding cytotoxic T lymphocytes from umbilical cord blood that target cytomegalovirus, Epstein-Barr virus, and adenovirus.

Authors:  Patrick J Hanley; Sharon Lam; Elizabeth J Shpall; Catherine M Bollard
Journal:  J Vis Exp       Date:  2012-05-07       Impact factor: 1.355

6.  Generation of tumor antigen-specific T cell lines from pediatric patients with acute lymphoblastic leukemia--implications for immunotherapy.

Authors:  Gerrit Weber; Ignazio Caruana; Rayne H Rouce; A John Barrett; Ulrike Gerdemann; Ann M Leen; Karen R Rabin; Catherine M Bollard
Journal:  Clin Cancer Res       Date:  2013-07-09       Impact factor: 12.531

Review 7.  T lymphocytes targeting native receptors.

Authors:  Cliona M Rooney; Ann M Leen; Juan F Vera; Helen E Heslop
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

8.  Kinetics of tumor destruction by chimeric antigen receptor-modified T cells.

Authors:  Usanarat Anurathapan; Robert C Chan; Hakeem F Hindi; Roopa Mucharla; Pradip Bajgain; Brendan C Hayes; William E Fisher; Helen E Heslop; Cliona M Rooney; Malcolm K Brenner; Ann M Leen; Juan F Vera
Journal:  Mol Ther       Date:  2013-11-28       Impact factor: 11.454

9.  Large-scale ex vivo expansion and characterization of natural killer cells for clinical applications.

Authors:  Natalia Lapteva; April G Durett; Jiali Sun; Lisa A Rollins; Leslie L Huye; Jian Fang; Varada Dandekar; Zhuyong Mei; Kimberley Jackson; Juan Vera; Jun Ando; Minhtran C Ngo; Elaine Coustan-Smith; Dario Campana; Susann Szmania; Tarun Garg; Amberly Moreno-Bost; Frits Vanrhee; Adrian P Gee; Cliona M Rooney
Journal:  Cytotherapy       Date:  2012-08-17       Impact factor: 5.414

10.  Generation of multi-leukemia antigen-specific T cells to enhance the graft-versus-leukemia effect after allogeneic stem cell transplant.

Authors:  G Weber; U Gerdemann; I Caruana; B Savoldo; N F Hensel; K R Rabin; E J Shpall; J J Melenhorst; A M Leen; A J Barrett; C M Bollard
Journal:  Leukemia       Date:  2013-03-01       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.